



February 5, 2018

Pharmacy Announcement

Pharmacy and Therapeutics (P&T) Committee Makes Changes to Preferred Drug List (PDL) Effective February 5, 2018

On December 7, 2017, the Pharmacy and Therapeutics (P&T) committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective February 5, 2018. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added As Preferred	Drugs Added As Non-Preferred
Analgesics: Opiate Agonists - Abuse Deterrent		Morphabond®
Anti-infective Agents: Antivirals - Anti-hepatitis Agents - Polymerase Inhibitors/Combination Products	Mavyret®	Vosevi®
Biologic Response Modifiers: Immunomodulators - Targeted Immunomodulators	Actemra® Inflectra®	Dupixent®
Dermatological Agents: Topical Analgesics	Capsaicin® Flector® Lidocaine/Prilocaine Pennsaid®	Diclofenac (gel and sol)
Dermatological Agents: Topical Anti-inflammatory Agents - Immunomodulators: Topical	Eucria® (oint)	
Gastrointestinal Agents - Functional Gastrointestinal Disorder Drugs		Symproic® Trulance®
Ophthalmic Agents: Ophthalmic Antihistamines		Olopatadine (drop and sol)
Respiratory Agents: Respiratory Anti-inflammatory Agents - Respiratory Corticosteroids		Armonair®
Respiratory Agents – Respiratory Long-Acting Antimuscarinic/Long-Acting Beta-Agonist Combinations	Bevespi®	